1042 / 1068
NCT01671488 phase I/II trial
Inclusion: T2
>4cm
-T4 or N+ M0, HIV neg
Primary Endpoints: SAE, CR at 6 months
MMC 10 mg/m²/d1
ADXS11-001*
q 28 days
5-FU 800/m²/d1-4
Standard RT: 45-65 Gy (IMRT mandatory)
*attenuated Listeria monocytogenes: secretes a protein fused to HPV E7 leading to
stimulation of cell-mediated immune response